I asked “How does Imugene’s adjuvant immunotherapy compare with the immunotherapy given to Richard Scolyer?"
3 seconds later, the artificially intelligent answer was
"Imugene’s adjuvant immunotherapy and the experimental immunotherapy given to Richard Scolyer differ in their mechanisms, targets, and overall therapeutic approaches. Here’s a detailed comparison:### Imugene’s Adjuvant Immunotherapy: PD1-Vaxx**Mechanism of Action**:- **Active Immunization**: PD1-Vaxx is designed to stimulate the patient's immune system to produce antibodies against the PD-1 protein. This differs from passive immunotherapies where antibodies are directly administered.- **Checkpoint Inhibition**: By generating antibodies that block PD-1, PD1-Vaxx enhances T-cell activation and proliferation, allowing the immune system to better recognize and attack cancer cells.**Target**:- **PD-1 Protein**: PD1-Vaxx specifically targets the PD-1 protein on T cells, a checkpoint inhibitor that downregulates immune responses. Blocking PD-1 can prevent tumors from evading immune detection.**Administration**:- **Vaccine Form**: PD1-Vaxx is administered as a vaccine, prompting the body to produce its own antibodies against PD-1. This can potentially lead to a more sustained and durable immune response.**Use in Cancer Patients**:- **Broad Applicability**: While currently focused on non-small cell lung cancer (NSCLC), PD1-Vaxx could potentially be used for other cancers expressing PD-1.### Richard Scolyer’s Experimental Immunotherapy**Mechanism of Action**:- **Checkpoint Inhibitor**: Scolyer’s treatment included pembrolizumab (Keytruda), a monoclonal antibody that directly blocks the PD-1 receptor on T cells.- **Neoadjuvant and Adjuvant Therapy**: Pembrolizumab was given before and after surgery to reduce tumor size and prevent recurrence, respectively.**Target**:- **PD-1 Protein**: Like PD1-Vaxx, pembrolizumab targets the PD-1 protein but does so through direct administration of the antibody rather than inducing the body to produce it.**Administration**:- **Monoclonal Antibody**: Pembrolizumab is administered via infusion, providing immediate but temporary checkpoint inhibition.- **Personalized Approach**: In addition to pembrolizumab, Scolyer received personalized peptide vaccines based on the specific mutations in his tumor, aiming to stimulate a targeted immune response.**Use in Cancer Patients**:- **Specific Case of Glioblastoma**: Scolyer’s treatment was tailored to his glioblastoma, a type of brain cancer. This personalized approach aimed to address the unique characteristics of his tumor.### Key Differences1. **Mechanism of Action**: - **Active vs. Passive Immunization**: PD1-Vaxx induces the body to produce its own antibodies against PD-1, whereas pembrolizumab involves the direct administration of PD-1 blocking antibodies. - **Combined Therapies**: Scolyer’s treatment involved a combination of pembrolizumab and personalized peptide vaccines, representing a multi-faceted approach to immunotherapy.2. **Target**: - Both therapies target the PD-1 checkpoint but differ in their method of achieving this.3. **Administration**: - **Vaccine vs. Infusion**: PD1-Vaxx is administered as a vaccine, potentially offering a longer-lasting immune response, whereas pembrolizumab is given as an infusion with a more immediate but less sustained effect. - **Personalization**: Scolyer’s treatment included personalized vaccines based on his tumor’s specific mutations, adding a layer of customization to his therapy.4. **Therapeutic Context**: - **Adjuvant Therapy**: PD1-Vaxx is being developed primarily for use in solid tumors like NSCLC and potentially others, serving as an adjuvant therapy. - **Comprehensive Treatment**: Scolyer’s therapy was a comprehensive, personalized treatment approach aimed at his specific glioblastoma, involving both neoadjuvant and adjuvant phases.### ConclusionImugene’s PD1-Vaxx and the experimental immunotherapy given to Richard Scolyer both target the PD-1 checkpoint but differ significantly in their approach and application. PD1-Vaxx focuses on active immunization to produce a sustained immune response, while Scolyer’s treatment involved a direct checkpoint inhibitor combined with personalized vaccines, tailored to his specific type of cancer. Each approach has its unique advantages and potential applications, contributing to the evolving landscape of cancer immunotherapy.”
Well thank you Chat, but I’m smart enough to do my own research
!!!!!
IMU Price at posting:
6.4¢ Sentiment: Buy Disclosure: Held
(20min delay)